Dermatology Times
JULY 10, 2024
The international study represents the most comprehensive analysis of Southeast Asian patients with CI to date and provides a detailed look into specific CI subtypes.
MedEsthetics
JULY 10, 2024
200+ decision-maker survey respondents shared their experiences with advancing marketing and creative initiatives, their points of view on where agency partners provide value and what role empathetic thinking plays in this work.
Lipgloss and Aftershave
JULY 10, 2024
How Chemical Peels Can Improve the Well Being of the Skin’s Barrier Join Barbara Devlin, educator, and distributor of Anna Lotan PRO Skincare to learn how modern chemical peels can improve the well-being of the skin’s barrier. Anna Lotan PRO uses a potent blend of 4 AHAs, 1 PHA, and enzymes for correction in addition to moisturizing and antioxidant-packed ingredients to aid in comfort and the well-being of the skin barrier.
Dermatology Times
JULY 10, 2024
A recent review suggested there may be a higher risk of AA development after COVID-19 vaccination in patients with a history of AA or thyroid dysfunction.
Lipgloss and Aftershave
JULY 10, 2024
Hale & Hush, a leading sensitive skin brand continues to grow! When L+A met Hale & Hush in 2017, the brand had a dozen or so products, several of which were mindful of those with cancer. They made their mark in the medical + spa skin care industry as a go-to brand to treat sensitive skin, reactive skin, and Rosacea. Over the past 7 years, the brand has grown its client base.
MedEsthetics
JULY 10, 2024
The initiative supports the rise of regenerative, longevity-focused beauty.
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
Skin Inc
JULY 10, 2024
200+ decision-maker survey respondents shared their experiences with advancing marketing and creative initiatives, their points of view on where agency partners provide value and what role empathetic thinking plays in this work.
Dermatology Times
JULY 10, 2024
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, have a comprehensive discussion on treatment safety considerations for patients with atopic dermatitis who are breastfeeding.
The Dermatology Digest
JULY 10, 2024
The National Institute for Health and Care Excellence (NICE) now recommends lebrikizumab (Ebglyss, Almirall S.A.) for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.
Dermatology Times
JULY 10, 2024
Looking to the future of atopic dermatitis treatment, Drs Kiracofe and Murase offer concluding remarks on current unmet needs, the benefits of treatment guidelines, and the importance of treating itch in patients who are or may become pregnant.
Dermatology Times
JULY 10, 2024
Alexandra Golant, MD, reviewed the complexities of managing atopic dermatitis with a focus on hand and foot involvement.
Dermatology Times
JULY 10, 2024
Cutiss plans to have full phase 2 data in early 2025.
Dermatology Times
JULY 10, 2024
Results showed that the most common nail concerns associated with or independent of hair loss included pitting, ridging, and white spots.
Expert insights. Personalized for you.
78 
Let's personalize your content